BIOMIMETIC THERAPEUTICS, INC.
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | |
|---|---|---|---|
| Revenue | $1.7M | $1.5M | $1.6M |
| Operating income | −$30.4M | −$34.6M | −$34.9M |
| Net income | −$33.2M | −$33.9M | −$21.2M |
| Total assets | $74.9M | $105.6M | — |
| Total liabilities | $20.9M | $22.4M | — |
| Equity | $54.0M | $83.1M | $67.1M |
| EPS (diluted) | — | — | — |
| Shares out. | 28.1M | 27.9M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −1759.5%
- Net margin
- −1924.1%
- Return on equity
- −61.4%
- Return on assets
- −44.3%
- Return on capital (ROCE)
- −44.4%
- Liabilities / assets
- 27.9%
- Debt / equity
- 0.39×
- Book value / share
- $1.92
- Revenue growth (YoY)
- 17.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Altman Z″ (distress)
- -1.73distress
- Accruals / assets
- −6.1%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeMar 6, 2013
- Shareholder voteFeb 26, 2013
- Other material eventFeb 12, 2013
- Other material eventFeb 5, 2013
- Other material eventJan 14, 2013
- Other material eventJan 7, 2013
- Other material eventJan 3, 2013
- Director / officer change · Other material eventDec 24, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 11, 2014
- 4/AFORM 4/A SUBMISSIONMar 18, 2013
- EFFECTMar 15, 2013
- EFFECTMar 15, 2013
- 15-12GMar 15, 2013
- SC 13D/AMar 13, 2013
- S-8 POSAMENDMENT NO. 1Mar 11, 2013
- S-8 POSAMENDMENT NO. 1Mar 11, 2013
- S-8 POSAMENDMENT NO.1Mar 11, 2013
- S-8 POSAMENDMENT NO.1Mar 11, 2013
- POS AMMar 11, 2013
- POS AMMar 11, 2013
- 4FORM 4 SUBMISSIONMar 6, 2013
- 4FORM 4 SUBMISSIONMar 6, 2013
- 8-KFORM 8-KMar 6, 2013